Question 1

What is Alladapt Immunotherapeutics?

Accepted Answer

Alladapt Immunotherapeutics is a Entity.

Question 2

How often does Alladapt Immunotherapeutics appear in global news?

Accepted Answer

Tracked across 5 news events drawn from 30 articles.

Question 3

When was Alladapt Immunotherapeutics first tracked by Ergen?

Accepted Answer

First tracked on Oct 16, 2025.

Question 4

When was Alladapt Immunotherapeutics last mentioned in news?

Accepted Answer

Last active on May 26, 2026.

Question 5

What is Alladapt Immunotherapeutics's current news sentiment?

Accepted Answer

Aggregate sentiment score: -42 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Alladapt Immunotherapeutics in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 5 events.

Question 7

What is the most recent event involving Alladapt Immunotherapeutics?

Accepted Answer

MoonLake Immunotherapeutics Class Action Lawsuit (Oct 16, 2025, 6 articles).

Question 8

How did the "MoonLake Immunotherapeutics Class Action Lawsuit" event impact Alladapt Immunotherapeutics?

Accepted Answer

Alladapt Immunotherapeutics is the defendant in a class action lawsuit, accused of making false and misleading statements regarding its drug SLK, which could lead to significant financial damages and reputational harm.

Question 9

How did the "MoonLake Immunotherapeutics faces class action" event impact Alladapt Immunotherapeutics?

Accepted Answer

Alladapt Immunotherapeutics is facing a securities fraud class action lawsuit for allegedly making misrepresentations about its drug candidate, sonelokimab (SLK), which could negatively impact its stock price and reputation.

Question 10

How did the "MoonLake Immunotherapeutics faces class action" event impact Alladapt Immunotherapeutics?

Accepted Answer

Alladapt Immunotherapeutics is facing a securities class action lawsuit due to allegedly false and misleading statements regarding its drug candidate SLK, which may have artificially inflated its stock price.

Question 11

How did the "MoonLake Immunotherapeutics Securities Lawsuit" event impact Alladapt Immunotherapeutics?

Accepted Answer

Alladapt Immunotherapeutics, Inc. is the defendant in a securities class action lawsuit, accused of concealing material adverse facts regarding its drug SLK's clinical performance and competitive positioning, leading to a 90% stock price drop.

Question 12

How did the "OSE Immunotherapeutics Tedopi® Phase 2 Results" event impact Alladapt Immunotherapeutics?

Accepted Answer

Alladapt Immunotherapeutics announced that topline results from its TEDOVA Phase 2 clinical trial of Tedopi® in Ovarian Cancer have been selected for an oral presentation at the 2026 ASCO Annual Meeting. This is a significant step in the development of its lead product.

Question 13

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.